Actively Recruiting
Senicapoc in Alzheimer's Disease
Led by University of California, Davis · Updated on 2026-01-29
55
Participants Needed
2
Research Sites
219 weeks
Total Duration
On this page
Sponsors
U
University of California, Davis
Lead Sponsor
A
Alzheimer's Drug Discovery Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans with early AD. The investigators will study up to 55 patients over 52 weeks, with primary outcomes being Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) scores and blood and cerebrospinal fluid (CSF) markers of neuroinflammation. This pilot study will provide an estimate of treatment effect size on cognitive trajectory, daily function, and brain atrophy.
CONDITIONS
Official Title
Senicapoc in Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 55 to 85 years
- Fluent in English or Spanish
- Willing to be randomly assigned to receive 10 mg Senicapoc or placebo
- Clinical Dementia Rating (CDR) global score of 0.5 or 1
- Montreal Cognitive Assessment (MoCA) score between 12 and 28 at screening
- Diagnosed with amnestic mild cognitive impairment or mild Alzheimer's disease dementia
- Vision of at least 20/50 with or without correction
- Have a study partner who has at least 6 hours of contact per week
- For females of childbearing potential: agree to use highly effective contraception throughout the study until week 78 follow-up visit
You will not qualify if you...
- Unstable medical conditions including liver or kidney insufficiency
- Unstable ischemic cardiovascular disease, respiratory failure, moderate to severe heart failure, cancer, unstable blood disorders, or life expectancy less than 3 years
- Use of experimental Alzheimer's disease treatments
- Unable to have MRI scan (due to pacemaker, implants, or severe claustrophobia)
- History of chronic psychiatric illness, recent major depression, suicidal thoughts or attempts
- Serious brain infections or head trauma causing lasting cognitive deficits
- Alcohol or drug abuse within past 5 years
- Known allergy to related compounds like clotrimazole
- Poor venous access preventing multiple blood draws
- Regular use of certain central nervous system medications unless approved and stable
- Pregnant or breastfeeding females or planning pregnancy during the trial
- Unable to swallow oral tablets
- For cerebrospinal fluid sub-study: implanted shunt or catheter, bleeding disorders, recent anticoagulant or antiplatelet therapy, abnormal clotting labs
- For PET sub-study: poor venous access, high recent radiation exposure, or low amyloid PET scan values
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University of California, Davis Alzheimer's Disease Center
Sacramento, California, United States, 95817
Actively Recruiting
2
UC Davis Alzheimer's Disease Center East Bay
Walnut Creek, California, United States, 94598
Actively Recruiting
Research Team
R
Rita Venua
CONTACT
S
Selene Leal Carrillo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here